Kalshi launches a biotech pilot, starting with 13 biotech contracts offering wagers on the outcomes of late-stage clinical drug trials and regulatory decisions
Kalshi began as a yes/no event-trading startup and has since added features aimed at more sophisticated users, including a margin-trading license. More recently, the company has said businesses are using its contracts to hedge risks, alongside rapid growth in institutional volume.
This pilot extends that model into a domain where discrete trial readouts and regulatory decisions can be turned into tradable events. It is a test of whether prediction-market infrastructure can support narrower, expertise-intensive risk markets rather than only broad public events.
First-order effects
Kalshi adds 13 biotech contracts tied to late-stage clinical-trial outcomes and regulatory decisions, giving traders a new set of event markets to buy and sell.
The launch broadens Kalshi’s addressable user base from general event-market participants toward traders and businesses with exposure to biotech milestones.
Second-order effects
Biotech investors and companies gain a public, continuously updating market signal around specific catalysts; whether that signal proves useful will depend on liquidity and contract design.
The pilot raises the bar for rival prediction platforms to offer specialized, professionally oriented markets, particularly as Kalshi has been building institutional-facing capabilities.
Third-order effects
If specialized contracts attract sustained liquidity, prediction markets could evolve from broad forecasting venues into a layer of market infrastructure for hedging event-driven business risk.
That expansion would put greater emphasis on the governance of markets tied to sensitive information-rich events, including how platforms define outcomes and monitor trading integrity.
The trend: Prediction-market platforms are moving from generalized wagers toward verticalized event contracts designed to serve professional risk and information use cases.
Interesting move. Genuine question on the insider surface, though: campaign insiders can be screened against FEC records, but trial staff, site investigators, and safety-board members are confidential by design. https://www.bloomberg.com/...
This will literally destroy lives and get people killed. Kalshi will incentivize third parties to destroy the integrity of double-blind clinical trials, on which we ALL depend. Politicians should ban it and return donations from Kalshi execs. https://www.bloomberg.com/...
So they finally did it Kalshi is opening prediction markets for clinical trials Dissatisfied patients enrolled in an obesity trial can now monetize their experience Hard to see how this will advance new drugs https://www.statnews.com/...
@DrSamuelBHume A patient may have good treatment response even if the trial fails, but if they are encouraged to dropout by random peoples' prediction odds, then you are depriving a patient from this and since they dropped out of a trial typically means they would be excluded fro…
I know people, personally, who have gone to jail for insider trading. This? This is an end run around that. — Awesome. I'm sure it won't backfire in any important ways or cause people to lie about drug efficacy in the hopes of making a buck. — www.statnews.com/2026/07/16/ …
I...I am honestly speechless. This is the end of medical and scientific research in the US as a reliable standard. No data will be reliable. www.bloomberg.com/news/article...
I just do not see how this _adds_ anything positive to the world — Kalshi says it's great bc ppl can now make investment decisions on individual drugs instead of whole companies — OK? So? — www.statnews.com/2026/07/16/ k...
“Michael Selig, the chair of the Commodity Futures Trading Commission that regulates prediction markets, has also touted drug-trial contracts as a potential way for sick people in need of medicine to hedge their future treatment costs.” — www.bloomberg.com/news/article...
You might not have an interest in financialization, but financialization has an interest in you. — “Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals” — www.statnews.com/2026/07/16/ k...
Having a hard time seeing upside for patients & science here: — “The main purpose of the trial is information-seeking. We are trying to find truth, and we're trying to advance medicine,” Zaorsky said. “Once you start to introduce all these other incentives, that main objectiv…